Financial reports
10-Q
2024 Q1
Quarterly report
24 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
25 Oct 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
10-K
2022 FY
Annual report
21 Feb 23
10-Q
2022 Q3
Quarterly report
21 Oct 22
10-Q
2022 Q2
Quarterly report
22 Jul 22
10-Q
2022 Q1
Quarterly report
22 Apr 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Results of Operations and Financial Condition
23 Apr 24
8-K
Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
1 Feb 24
8-K
Quest Diagnostics Prices $750 Million of Senior Notes
1 Nov 23
8-K
Updates Guidance for Full Year 2023
24 Oct 23
8-K
Departure of Directors or Certain Officers
29 Sep 23
8-K
Updates Guidance for Full Year 2023
26 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
8-K
Updates Guidance for Full Year 2023
27 Apr 23
8-K
Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and Create Shareholder Value at 2023 Investor Day
17 Mar 23
8-K
Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board
7 Mar 23
Registration and prospectus
424B2
Prospectus for primary offering
31 Oct 23
FWP
Free writing prospectus
30 Oct 23
424B2
Prospectus for primary offering
30 Oct 23
S-8
Registration of securities for employees
27 Oct 23
S-3ASR
Automatic shelf registration
25 Jul 22
424B2
Prospectus for primary offering
13 May 20
FWP
Free writing prospectus
11 May 20
424B2
Prospectus for primary offering
11 May 20
424B2
Prospectus for primary offering
10 Dec 19
FWP
Free writing prospectus
9 Dec 19
Proxies
PX14A6G
Letter to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
PX14A6G
Letter to shareholders
10 Apr 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
PX14A6G
Letter to shareholders
22 Apr 22
DEF 14A
Definitive proxy
18 Apr 22
PRE 14A
Preliminary proxy
4 Apr 22
Other
CT ORDER
Confidential treatment order
27 Mar 17
NO ACT
No action letter
23 Mar 17
UPLOAD
Letter from SEC
29 Apr 16
CORRESP
Correspondence with SEC
20 Apr 16
UPLOAD
Letter from SEC
7 Apr 16
NO ACT
No action letter
17 Mar 16
CT ORDER
Confidential treatment order
7 Dec 15
SD
Conflict minerals disclosure
29 May 14
NO ACT
No action letter
19 Feb 14
UPLOAD
Letter from SEC
7 May 13
Ownership